Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes

被引:24
作者
Bianchi, Cristina [1 ]
Daniele, Giuseppe [1 ]
Dardano, Angela [1 ]
Miccoli, Roberto [1 ]
Del Prato, Stefano [1 ]
机构
[1] Univ Pisa, Nuovo Osped Santa Chiara, Dept Clin & Expt Med, Sect Diabet & Metab Dis, Via Paradisa, I-56124 Pisa, Italy
关键词
BETA-CELL FUNCTION; FIXED-DOSE COMBINATION; DRUG-NAIVE PATIENTS; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ADD-ON THERAPY; SUPERIOR GLYCEMIC CONTROL; INITIAL COMBINATION; DOUBLE-BLIND; PLUS METFORMIN; COMPONENT MONOTHERAPY;
D O I
10.1007/s40265-017-0694-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite the considerable burden of disease associated with type 2 diabetes mellitus (T2DM), most patients are not at, or are unable to achieve, recommended glycemic targets. This is partly because of the relentless progressive nature of the disease, but it may also be attributable to the current diabetes treatment paradigm. The recommended stepwise approach may lead to frequent early treatment failure with prolonged periods of elevated glucose as a consequence of clinical inertia and delays in achieving optimal glycemic control. Thus, it is most appropriate to consider the current treatment paradigm for T2DM in the context of a more aggressive initial therapy with early combination therapy. Current guidelines advise that initial combination therapy should be used for patients presenting with elevated glycated hemoglobin (HbA(1c)). However, several studies and recent meta-analyses suggest a potential benefit from initial combination therapy on glycemic outcomes in diabetes compared with metformin monotherapy across a wide range of baseline HbA(1c) levels. Indeed, combination therapy can increase the number of patients achieving glycemic goals, and the newer glucose-lowering agents may reduce the risk of hypoglycemia and body weight gain. Moreover, our improving understanding of the complex pathophysiology of T2DM and the availability of treatments tackling specific mechanisms contributing to hyperglycemia should lead to more pathophysiologically sound combination therapy. We discuss the rationale behind and evidence for early combination therapy as well as what is needed in the future to better understand its potential.
引用
收藏
页码:247 / 264
页数:18
相关论文
共 95 条
[1]   Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial [J].
Abdul-Ghani, M. A. ;
Puckett, C. ;
Triplitt, C. ;
Maggs, D. ;
Adams, J. ;
Cersosimo, E. ;
DeFronzo, R. A. .
DIABETES OBESITY & METABOLISM, 2015, 17 (03) :268-275
[2]   Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism [J].
Ahren, Bo ;
Foley, James E. .
DIABETOLOGIA, 2016, 59 (05) :907-917
[3]  
[Anonymous], 1995, DIABETES, DOI DOI 10.2337/DIAB.44.11.1249
[4]   Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [J].
Avogaro, Angelo ;
Fadini, Gian Paolo ;
Sesti, Giorgio ;
Bonora, Enzo ;
Del Prato, Stefano .
CARDIOVASCULAR DIABETOLOGY, 2016, 15
[5]   A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients [J].
Borges, J. L. C. ;
Bilezikian, J. P. ;
Jones-Leone, A. R. ;
Acusta, A. P. ;
Ambery, P. D. ;
Nino, A. J. ;
Grosse, M. ;
Fitzpatrick, L. A. ;
Cobitz, A. R. .
DIABETES OBESITY & METABOLISM, 2011, 13 (11) :1036-1046
[6]   Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus [J].
Bosi, E. ;
Dotta, F. ;
Jia, Y. ;
Goodman, M. .
DIABETES OBESITY & METABOLISM, 2009, 11 (05) :506-515
[7]   The burden of treatment failure in type 2 diabetes [J].
Brown, JB ;
Nichols, GA ;
Perry, A .
DIABETES CARE, 2004, 27 (07) :1535-1540
[8]   Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes [J].
Cahn, Avivit ;
Cefalu, William T. .
DIABETES CARE, 2016, 39 :S137-S145
[9]   Medication Adherence With Diabetes Medication: A Systematic Review of the Literature [J].
Capoccia, Kam ;
Odegard, Peggy S. ;
Letassy, Nancy .
DIABETES EDUCATOR, 2016, 42 (01) :34-71
[10]   Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes [J].
Chou, H. S. ;
Palmer, J. P. ;
Jones, A. R. ;
Waterhouse, B. ;
Ferreira-Cornwell, C. ;
Krebs, J. ;
Goldstein, B. J. .
DIABETES OBESITY & METABOLISM, 2008, 10 (08) :626-637